Treprostinil
Treprostinil is a prostacyclin mimetic. This page records what three US labels from one sponsor say, one for each route. The label for Remodulin, an injection formulated for subcutaneous or intravenous administration, lists pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise and, separately, for patients who require transition from epoprostenol, reducing the rate of clinical deterioration. The label for Tyvaso, a sterile solution for oral inhalation, lists PAH to improve exercise ability and, separately, pulmonary hypertension associated with interstitial lung disease (WHO Group 3) to improve exercise ability. The label for Orenitram, extended-release tablets, lists PAH to delay disease progression and to improve exercise capacity. Each statement belongs to its own label and route.
Also called Remodulin · TYVASO · Orenitram · Treprostinil sodium · Treprostinil diolamine
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 343048; UNII RUM6K67ESG. MeSH has no descriptor for treprostinil (name lookups on 2026-11-18 found only supplementary concept terms), so no MeSH identifier is recorded. RxClass lists the established pharmacologic class spelled Prostacycline Vasodilator, so the record is filed under the prostacyclin pathway page. The labels read, all by United Therapeutics Corporation, are Remodulin (NDA021272, effective 2026-07-02 in openFDA), Tyvaso (NDA022387, effective 2026-04-14) and Orenitram (NDA203496, effective 2024-11-20). Other treprostinil products and labels, including other inhaled products, were not read. Drugs@FDA lists the ingredient strings treprostinil, treprostinil sodium and treprostinil diolamine; the two salt names are kept as aliases. The statements sit in separate claims and contexts, and none gives a dose or an instruction.
About this drug
- Level
- Substance
- Mechanism
- The Remodulin label says the major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds, and inhibition of platelet aggregation.
Claims and evidence
Context Patients with pulmonary arterial hypertension who require transition from epoprostenol, as described in the US label of Remodulin
- Recipient
- Recipient not specified
- Population
- Patients who require transition from epoprostenol, as the label states. The passage read gives no age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the passage read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients who require transition from epoprostenol, as the label states. The passage read gives no age range.
- Excluded
- None stated
The same US label of Remodulin separately lists, for patients who require transition from epoprostenol, reducing the rate of clinical deterioration.
Applies to Recipient not specified Patients with pulmonary arterial hypertension who require transition from epoprostenol, as described in the US label of Remodulin
- Certainty method
- Not assessed
- Limitations
- This claim is tied to the Remodulin injection label only, and to the transition use the label names. It does not say how a transition is done, and no instruction is recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA021272.
- Retrieved
- Source effective date
- 2026-07-02
- Source state
- Current
- Version fingerprint
8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260702.
- Retrieved
- Source effective date
- 2026-07-02
- Source state
- Current
- Version fingerprint
8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (Q-K30-TRE-RE-05).
- Retrieved
- Source effective date
- 2026-07-02
- Source state
- Current
- Version fingerprint
8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Patients with pulmonary arterial hypertension, as described in the US label of Orenitram
- Recipient
- Recipient not specified
- Population
- Patients with pulmonary arterial hypertension (PAH) (WHO Group 1), as the label states. The passage read gives no age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the passage read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients with pulmonary arterial hypertension (PAH) (WHO Group 1), as the label states. The passage read gives no age range.
- Excluded
- None stated
The US label of Orenitram (treprostinil extended-release tablets, United Therapeutics Corporation, application NDA203496; the version dated 2024-11-20 in openFDA) calls the medicine a prostacyclin mimetic. It lists treating pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity.
Applies to Recipient not specified Patients with pulmonary arterial hypertension, as described in the US label of Orenitram
- Certainty method
- Not assessed
- Limitations
- This claim is tied to the Orenitram tablet label only. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA203496.
- Retrieved
- Source effective date
- 2024-11-20
- Source state
- Current
- Version fingerprint
d8a098270f8df7a60f3ab00c587921a8e61696526f26db8b624881165be822b0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20241120.
- Retrieved
- Source effective date
- 2024-11-20
- Source state
- Current
- Version fingerprint
d8a098270f8df7a60f3ab00c587921a8e61696526f26db8b624881165be822b0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (Q-K30-TRE-OR-03, Q-K30-TRE-OR-04, Q-K30-TRE-OR-05).
- Retrieved
- Source effective date
- 2024-11-20
- Source state
- Current
- Version fingerprint
d8a098270f8df7a60f3ab00c587921a8e61696526f26db8b624881165be822b0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Patients with pulmonary arterial hypertension, as described in the US label of Remodulin
- Recipient
- Recipient not specified
- Population
- Patients with pulmonary arterial hypertension (PAH; WHO Group 1), as the label states. The passage read gives no age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the passage read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients with pulmonary arterial hypertension (PAH; WHO Group 1), as the label states. The passage read gives no age range.
- Excluded
- None stated
The US label of Remodulin (treprostinil injection, United Therapeutics Corporation, application NDA021272; the version dated 2026-07-02 in openFDA) calls the medicine a prostacyclin mimetic, formulated for subcutaneous or intravenous administration. It lists treating pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise.
Applies to Recipient not specified Patients with pulmonary arterial hypertension, as described in the US label of Remodulin
- Certainty method
- Not assessed
- Limitations
- This claim is tied to the Remodulin injection label only. The inhaled and oral treprostinil products have their own labels and claims. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists a transition use, which sits in a separate claim.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA021272.
- Retrieved
- Source effective date
- 2026-07-02
- Source state
- Current
- Version fingerprint
8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260702.
- Retrieved
- Source effective date
- 2026-07-02
- Source state
- Current
- Version fingerprint
8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (Q-K30-TRE-RE-03, Q-K30-TRE-RE-04, Q-K30-TRE-RE-06).
- Retrieved
- Source effective date
- 2026-07-02
- Source state
- Current
- Version fingerprint
8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Patients with pulmonary arterial hypertension, as described in the US label of Tyvaso
- Recipient
- Recipient not specified
- Population
- Patients with pulmonary arterial hypertension (PAH; WHO Group 1), as the label states. The passage read gives no age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the passage read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients with pulmonary arterial hypertension (PAH; WHO Group 1), as the label states. The passage read gives no age range.
- Excluded
- None stated
The US label of Tyvaso (treprostinil, a sterile solution for oral inhalation, United Therapeutics Corporation, application NDA022387; the version dated 2026-04-14 in openFDA) calls the medicine a prostacyclin mimetic. It lists treating pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability.
Applies to Recipient not specified Patients with pulmonary arterial hypertension, as described in the US label of Tyvaso
- Certainty method
- Not assessed
- Limitations
- This claim is tied to the Tyvaso inhalation solution label only. Other inhaled treprostinil products have their own labels and were not read. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists pulmonary hypertension with interstitial lung disease, which sits in a separate claim.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA022387.
- Retrieved
- Source effective date
- 2026-04-14
- Source state
- Current
- Version fingerprint
3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260414.
- Retrieved
- Source effective date
- 2026-04-14
- Source state
- Current
- Version fingerprint
3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (Q-K30-TRE-TY-03, Q-K30-TRE-TY-04, Q-K30-TRE-TY-06).
- Retrieved
- Source effective date
- 2026-04-14
- Source state
- Current
- Version fingerprint
3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Patients with pulmonary hypertension associated with interstitial lung disease, as described in the US label of Tyvaso
- Recipient
- Recipient not specified
- Population
- Patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3), as the label states. The passage read gives no age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the passage read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3), as the label states. The passage read gives no age range.
- Excluded
- None stated
The same US label of Tyvaso separately lists treating pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.
Applies to Recipient not specified Patients with pulmonary hypertension associated with interstitial lung disease, as described in the US label of Tyvaso
- Certainty method
- Not assessed
- Limitations
- This claim is tied to the Tyvaso inhalation solution label only, and concerns a different group of pulmonary hypertension from pulmonary arterial hypertension. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA022387.
- Retrieved
- Source effective date
- 2026-04-14
- Source state
- Current
- Version fingerprint
3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260414.
- Retrieved
- Source effective date
- 2026-04-14
- Source state
- Current
- Version fingerprint
3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (Q-K30-TRE-TY-03, Q-K30-TRE-TY-05, Q-K30-TRE-TY-06).
- Retrieved
- Source effective date
- 2026-04-14
- Source state
- Current
- Version fingerprint
3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label for the Remodulin injection lists pulmonary arterial hypertension (WHO Group 1), to diminish symptoms associated with exercise, as an indication: Pulmonary arterial hypertension
Applies to Recipient not specified Patients with pulmonary arterial hypertension, as described in the US label of Remodulin
The US label of Remodulin (treprostinil injection, United Therapeutics Corporation, application NDA021272; the version dated 2026-07-02 in openFDA) calls the medicine a prostacyclin mimetic, formulated for subcutaneous or intravenous administration. It lists treating pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise.Limitations. This claim is tied to the Remodulin injection label only. The inhaled and oral treprostinil products have their own labels and claims. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists a transition use, which sits in a separate claim.
-
Claim, not a settled fact FDA label for the Remodulin injection separately lists patients who require transition from epoprostenol as an indication: Pulmonary arterial hypertension
Applies to Recipient not specified Patients with pulmonary arterial hypertension who require transition from epoprostenol, as described in the US label of Remodulin
The same US label of Remodulin separately lists, for patients who require transition from epoprostenol, reducing the rate of clinical deterioration.Limitations. This claim is tied to the Remodulin injection label only, and to the transition use the label names. It does not say how a transition is done, and no instruction is recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
-
Claim, not a settled fact FDA label for the Tyvaso inhalation solution lists pulmonary arterial hypertension (WHO Group 1), to improve exercise ability, as an indication: Pulmonary arterial hypertension
Applies to Recipient not specified Patients with pulmonary arterial hypertension, as described in the US label of Tyvaso
The US label of Tyvaso (treprostinil, a sterile solution for oral inhalation, United Therapeutics Corporation, application NDA022387; the version dated 2026-04-14 in openFDA) calls the medicine a prostacyclin mimetic. It lists treating pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability.Limitations. This claim is tied to the Tyvaso inhalation solution label only. Other inhaled treprostinil products have their own labels and were not read. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists pulmonary hypertension with interstitial lung disease, which sits in a separate claim.
-
Claim, not a settled fact FDA label for the Tyvaso inhalation solution separately lists pulmonary hypertension associated with interstitial lung disease (WHO Group 3) as an indication: Pulmonary hypertension
Applies to Recipient not specified Patients with pulmonary hypertension associated with interstitial lung disease, as described in the US label of Tyvaso
The same US label of Tyvaso separately lists treating pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.Limitations. This claim is tied to the Tyvaso inhalation solution label only, and concerns a different group of pulmonary hypertension from pulmonary arterial hypertension. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
-
Claim, not a settled fact FDA label for the Orenitram tablets lists pulmonary arterial hypertension (WHO Group 1), to delay disease progression and to improve exercise capacity, as an indication: Pulmonary arterial hypertension
Applies to Recipient not specified Patients with pulmonary arterial hypertension, as described in the US label of Orenitram
The US label of Orenitram (treprostinil extended-release tablets, United Therapeutics Corporation, application NDA203496; the version dated 2024-11-20 in openFDA) calls the medicine a prostacyclin mimetic. It lists treating pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity.Limitations. This claim is tied to the Orenitram tablet label only. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
Record details
- Record id
cardio:treprostinil- Content hash
69b9164487a54e6855c1ec2c62f078bb13729a4a2c4a9eec80dd893797684bcc